Author Archive: Daniel Seaton

Daniel Seaton

Daniel Seaton is BIO's Director for Health Communications, where he handles communications on public policy issues affecting members of BIO's health and emerging company sections. Prior to joining BIO in August 2013, he spent four years in communications at the Pharmaceutical Research and Manufacturers of America. The best part of his job is educating audiences about the many benefits the bioscience industry produces for patients, consumers, and the economy as a whole. Daniel enjoys hiking, camping, and, when he can find a game, playing bridge. Having grown up in New Mexico, one of his favorite foods is roasted green chile. He has a Master's degree in Public Relations and Corporate Communications from Georgetown University.

Latest Posts

Patient and provider groups ask CMS: Don’t turn back the clock on rheumatic disease care

synthetic biology

Writing today in The Hill, Ann Palmer of the Arthritis Foundation and Joan Von Feldt of the American College of Rheumatology have a message for CMS: don’t turn back the clock on rheumatic disease care by proceeding with the recently proposed payment cuts in the Medicare Part B program. They write: The Centers for Medicare & Medicaid Services (CMS) recently proposed additional Medicare Part B payment cuts that would make it exceedingly more difficult for Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , ,

Evidence Mounts of Insurer Discrimination against HIV, HCV Patients

new-bio-logo

We’ve written before about the problem of discriminatory formulary design in health insurance plans, particularly for patients with high-cost health conditions. Evidence continues to mount that the practice is widespread and poses substantial barriers to accessing needed medicines for patients with potentially deadly and debilitating diseases like HIV and hepatitis C. Late last week, New York Attorney General Eric Schneiderman sued a health plan, alleging that it refused to pay for hepatitis C drugs except Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , ,

New Reports: Insurance Plans Shifting More Costs to Patients

KaiserFamFdn

A new report out this week from the Kaiser Family Foundation showed that patient out of pocket costs are increasing, as insurance plans shift a greater share of costs onto patients via increased deductibles and coinsurance payments. The study found that “between 2004 and 2014, average payments for deductibles and coinsurance rose considerably faster than the overall cost for covered benefits, while the average payments for copayments fell.” It showed that in the same time Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , ,

Morning Consult: Medicare’s Flawed Part B Drug Experiment Could Harm Patients

admin-ajax

In today’s Morning Consult, the Community Oncology Alliance’s Rose Gerber has an excellent piece detailing the potential harm to patients posed by the Medicare Part B demonstration proposed by CMS last month: For Medicare patients, the impacts of CMS’s experiment could be dire. Reducing reimbursement to patients’ physicians to the level proposed would make it impossible for many providers to offer the most clinically effective treatment options to patients – forcing patients to forego prescribed Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , ,

Judd Gregg: Biodefense Funding Is Crucial to National Security

ebola

Writing in the Morning Consult, former Senator Judd Gregg explains critical role of federal programs in preparing our nation for viral outbreaks and other biohazards that threaten to cause devastating harm to our national security. Because there is no commercial market for medical countermeasures to respond to attacks from chemical, biological, nuclear and radiological threats, in 2004 Congress passed the Project BioShield Act, which created the Project BioShield Special Reserve Fund (SRF) to incentivize research Read More >

Health, Public Policy  |  Leave a comment  |  Email This Post
Tags: , , ,